The House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug costs and strengthen the Affordable Care Act’s health insurance marketplaces. The legislation’s drug-related provisions would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief, and help decrease the time it takes for generic competitors to get to market. The ACA marketplace provisions would provide funding to expand navigator support and outreach to help consumers enroll in individual market coverage, and void a final rule that expanded short-term limited duration health plans. 
 

Headline
The Department of the Treasury and the Internal Revenue Service Oct. 14 released proposed regulations implementing several premium tax credit provisions…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model. The…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 18 that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in its…
Headline
The Trump administration announced Aug. 31 agreements with nine additional pharmaceutical manufacturers aimed at lowering prescription drug prices through a…
Headline
The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price…